Stock GANX GAIN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Real-time Estimate Cboe BZX
Other stock markets
 12:46:07 04/05/2024 am IST 		5-day change 1st Jan Change
2.92 USD -0.34% Intraday chart for Gain Therapeutics, Inc. -4.29% -11.18%
24/04 Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 CI
08/04 Gain Therapeutics Names Gene Mack as CFO MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Trims Price Target on Gain Therapeutics to $9 From $10, Keeps Buy Rating
MT
Maxim Starts Gain Therapeutics at Buy With $10 Price Target
MT
Chardan Raises Price Target on Gain Therapeutics to $6 From $5.75, Keeps Buy Rating
MT
Chardan Raises PT on Gain Therapeutics to $5.75 From $4 on Plans to Advance Lead Drug Candidate to Clinical Trials, Reiterates Buy Rating
MT
Chardan Ups Price Target on Gain Therapeutics to $5.75 From $4, as Lead Therapeutic Candidate Advances Into Clinic, Reiterates Buy Rating
MT
Chardan Initiates Gain Therapeutics With Buy Rating, Price Target is $4
MT
Oppenheimer Lowers Gain Therapeutics' Price Target to $10 From $30, Maintains Outperform Rating
MT
BTIG Lowers Price Target on Gain Therapeutics to $10 From $30, Maintains Buy Rating
MT
B. Riley Downgrades Gain Therapeutics to Neutral from Buy, Says Filing Delay of Parkinson's Disease Lead Candidate Worsens Financing Overhang; Lowers PT to $5 from $11
MT
B. Riley Lowers Gain Therapeutics' Price Target to $11 from $16 to Reflect Increased Long-Term Cost of Capital Amid Current Macro Conditions; Keeps Buy Rating
MT
B. Riley Lowers Gain Therapeutics' PT to $16 from $21 to Reflect Higher OpEx Spend Trajectory to Support Expanding Pipeline Activities, Keeps Buy Rating
MT
HC Wainwright Initiates Gain Therapeutics at Buy With $12 Price Target
MT
B. Riley Starts Gain Therapeutics at Buy with $21 PT, Encouraged by Drug Discovery Approach that Allows for Initial Focus on Lower-Risk Pipeline Programs
MT
GAIN THERAPEUTICS : Oppenheimer Initiates Coverage on Gain Therapeutics With Outperform Rating, $30 Price Target
MT
GAIN THERAPEUTICS : BTIG Research Initiates Coverage on Gain Therapeutics With Buy Rating, $30 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GANX Stock
  4. News Gain Therapeutics, Inc.
  5. Analyst Reco.